Healthcare -
Biotechnology - NASDAQ - US
$ 24.38
-5.39 %
$ 1.44 B
Market Cap
-19.05
P/E
CASH FLOW STATEMENT
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Janux Therapeutics, Inc.
| Net Income | -69 M |
| Depreciation & Amortization | 2.06 M |
| Capital Expenditures | -359 K |
| Stock-Based Compensation | 33 M |
| Change in Working Capital | 685 K |
| Others | -11.5 M |
| Free Cash Flow | -44.2 M |
Cash Flow
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (69.0) | (58.3) | (63.1) | (32.7) | (6.8) | (4.0) |
| Depreciation & Amortization | 2.1 | 2.0 | 0.8 | 0.1 | 13 K | 6 K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock Based Compensation | 33.0 | 20.0 | 17.2 | 6.9 | 72 K | 6 K |
| Other Operating Activities | (10.6) | (7.7) | (2.2) | (0.2) | 1.9 | 0.2 |
| Change in Working Capital | 0.7 | (6.6) | 4.3 | 8.8 | 0.4 | 69 K |
| Cash From Operations | (43.8) | (50.6) | (42.9) | (17.0) | (4.4) | (3.8) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | (0.4) | (1.9) | (6.4) | (1.5) | 0 | 0 |
| Other Items | (257.7) | (39.3) | 64.7 | (339.5) | 0 | 0 |
| Cash From Investing Activities | (258.0) | (41.2) | 58.3 | (341.0) | 0 | 0 |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 2.5 | 4.0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 15.0 | 3.0 | 0.5 | 182.4 | 18.0 | 0 |
| Cash From Financing Activities | 713.2 | 59.5 | 0.5 | 386.5 | 11.5 | 4.0 |
| CHANGE IN CASH | ||||||
| Net Change In Cash | 411.4 | (32.2) | 15.8 | 28.6 | 7.2 | 0.2 |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (44.2) | (52.4) | (49.4) | (18.5) | (4.4) | (3.8) |